Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Consensus Target Price from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of analysts recently commented on the company. Robert W. Baird dropped their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus decreased their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Alto Neuroscience Price Performance

ANRO opened at $3.72 on Friday. The firm’s fifty day moving average price is $5.75 and its two-hundred day moving average price is $9.77. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1 year low of $3.56 and a 1 year high of $24.00.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. On average, equities analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several large investors have recently modified their holdings of ANRO. Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience during the 1st quarter valued at approximately $8,233,000. Bank of New York Mellon Corp purchased a new stake in shares of Alto Neuroscience during the second quarter worth $252,000. Rhumbline Advisers bought a new position in shares of Alto Neuroscience in the second quarter worth $113,000. TD Asset Management Inc purchased a new position in shares of Alto Neuroscience in the second quarter valued at $928,000. Finally, Bowie Capital Management LLC bought a new stake in shares of Alto Neuroscience during the 2nd quarter valued at $462,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.